These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28898876)

  • 21. The risk of dyspnea in patients treated with third-generation P2Y
    Zhang N; Xu W; Li O; Zhang B
    BMC Cardiovasc Disord; 2020 Mar; 20(1):140. PubMed ID: 32183711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
    Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
    Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
    Roffman DS
    J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.
    Dalal JJ; Digrajkar A; Gandhi A
    Indian Heart J; 2016; 68(5):624-631. PubMed ID: 27773400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
    Alexopoulos D; Xanthopoulou I; Moulias A; Lekakis J
    J Am Coll Cardiol; 2016 Sep; 68(11):1223-1232. PubMed ID: 27609686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
    Qutub MA; Chong AY; So DY
    Can J Cardiol; 2015 Dec; 31(12):1481-4. PubMed ID: 26243350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
    Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
    Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
    Judge HM; Buckland RJ; Jakubowski JA; Storey RF
    Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
    Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J
    Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    Bavishi C; Panwar S; Messerli FH; Bangalore S
    Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.